Retatrutide: The Triple Agonist Redefining What’s Possible in Obesity Research
Compound Research Guide — Emerging Science · 8 min read · syntheralab.com
Retatrutide represents the next frontier of metabolic peptide research. As a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it has produced the largest weight loss results ever observed in a peptide-based clinical trial. Here is a comprehensive look at what the research shows.
Triple receptor mechanism
Retatrutide activates three distinct hormone receptors: GLP-1 (appetite and insulin regulation), GIP (glucose-dependent insulin stimulation and fat metabolism), and glucagon (energy expenditure, substrate utilization, and liver fat reduction). Researchers at UAB describe the glucagon component as particularly significant: its role extends beyond counterregulatory responses to include energy expenditure, protein metabolism, and — critically — hepatic lipid regulation.
Phase 2 obesity trial results
The landmark phase 2 trial of retatrutide was published in the New England Journal of Medicine in August 2023. In 338 adults with obesity and without type 2 diabetes, the highest dose of retatrutide (12 mg) produced a mean weight reduction of 24.2% of baseline body weight at 48 weeks. At this dose, 100% of participants achieved at least 5% weight loss, 93% achieved at least 10%, and 83% achieved at least 15%. Waist circumference reductions ranged up to 19.6 cm. Eli Lilly reported that this represented a mean loss of approximately 57.8 pounds.
Metabolic improvements beyond weight loss
Weight reductions were accompanied by improvements across multiple cardiometabolic markers. A systematic review and meta-analysis published in PMC in 2025 found that retatrutide significantly improved HbA1c levels, blood pressure, triglycerides, and LDL-cholesterol. Notably, 72% of participants with prediabetes at baseline reverted to normoglycemia during treatment. LDL cholesterol reductions of approximately 20% were observed, potentially reflecting glucagon agonism's effects on PCSK9 degradation.
Liver fat research — a breakthrough finding
A substudy published in Nature Medicine (2024) examined retatrutide's effects on metabolic dysfunction-associated steatotic liver disease (MASLD). At the highest doses, more than 80% of participants achieved at least 70% relative reduction in liver fat, and more than 85% achieved resolution of steatosis (defined as less than 5% total liver fat content). The mean relative reduction in liver fat was 82.4% at the 12 mg dose at 24 weeks. These results represent among the largest treatment effects ever reported for liver fat reduction.
Phase 3 and regulatory pathway
The TRIUMPH phase 3 development program is currently evaluating retatrutide for chronic weight management, obstructive sleep apnea, and knee osteoarthritis in people with obesity. Regulatory approval from the FDA is expected to require completion of these phase 3 trials, with projections extending through 2025 and into subsequent years depending on trial results. Retatrutide is currently available for in-vitro laboratory research only.
Research Sources
Jastreboff et al., NEJM (2023): At the highest dose (12 mg), retatrutide achieved 24.2% mean weight reduction at 48 weeks, with 100% of participants achieving at least 5% weight loss.
Sanyal et al., Nature Medicine (2024): Retatrutide reduced liver fat by up to 82.4% at 24 weeks — among the largest treatment effects ever reported for liver fat reduction.
Springer Triple Agonism Review (2025): Retatrutide achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity and 16.9% in those with T2D after 36 weeks, with 82% of T2D participants reaching HbA1c of 6.5% or below.
Eli Lilly Phase 2 Press Release: In a secondary endpoint, retatrutide demonstrated mean weight reduction up to 24.2% (57.8 lb) at the end of the 48-week treatment duration.
→ Retatrutide research kits available at syntheralab.com — the most advanced triple agonist compound now accessible for research.
